近年来人们对继承性免疫治疗的兴趣日益增长,多数集中在淋巴因子-激活杀伤(LAK)细胞和细胞毒性T淋巴细胞(CTL)的使用上。传统的方法从肿瘤浸润性淋巴细胞(TIL)取得CTL的数量有其限制性。实验证实了从周围血液生产较多量CTL的可行性。 按Bear介绍从鼠肿瘤细胞系P815选出的PHS-5突变种,置于8-氮杂鸟嘌呤中让其生长。PHS-5在次黄瞟呤氨基蝶呤和胸腺嘧啶核甙(HAT)中不生长,但仍保留与原细胞系相同的抗原性,在培养基中加入HAT可使淋 In recent years, there has been an increasing interest in the use of inherited immunotherapy, and the majority have focused on the use of lymphokine-activated killer (LAK) cells and cytotoxic T lymphocytes (CTL). The traditional method to obtain CTL from tumor infiltrating lymphocytes (TIL) is limited. Experiments confirmed the feasibility of producing more CTLs from peripheral blood. According to Bear, the PHS-5 mutant selected from the murine tumor cell line P815 was placed in 8-azaguanine for growth. PHS-5 does not grow in hypoxanthine aminopterin and thymidine nuclear (HAT) but still retains the same antigenicity as the original cell line.